Abstract Details

Title Headache as an Early Symptom and Post-Acute Sequela of COVID19 in Hospitalized COVID19 Survivors

Topic Headache

Presentation(s) S4 - Hot Topics in Headache Medicine (2:24 PM-2:36 PM)

Poster/Presentation
Number 008

Objective To evaluate acute and persistent headache in hospitalized COVID19 survivors.

Background Headache is a common symptom of acute COVID19 infection and Post-Acute Sequela of COVID19 (PASC); however, the clinical course and associated factors remain unknown.

Design/Methods

Of the 411 COVID19 patients hospitalized from February 2020 to November 2020 in a single center, a chart review was completed for the presence of headache during hospitalization. Patients were consented and interviewed at 12-month follow-up to assess headache, the clinical course of their symptoms, and associated factors with objective measures.

Results Among assessed, 17% reported headache (50/287). A total of 331 patients survived hospitalization. At 12-month follow-up, 43 patients were interviewed (mean age 65±15 years, 44% female, 74% White, 19% Black, 65% Hispanic, 58% Spanish speaking only). A total of 28% had new or worsening headache with COVID19 (58% female, 30% MIDAS grade III-IV). For the majority, the headache began within 7 days of diagnosis (75%); 12% had persistent attacks lasting > 3 months. Of those with a headache versus those without, 92% vs 65% reported an impact on lifestyle; 58% vs 23% on employment/ financial status, and 50% vs 23% on sleep. An average of 5 vs 2 symptoms lasting greater than three months was reported in the headache group vs no headache. Of those in the headache group vs no headache, 33% vs 13% reported persistent taste/smell abnormalities; 42% vs 26% persistent fatigue; 33% vs 16% persistent imbalance; and 25% vs 16% persistent cognitive impairment.

Conclusions In our racially/ethnically diverse cohort of hospitalized COVID19 patients, headache was a relatively common acute symptom. Persistent symptoms and psychosocial impact were common in those who had new or worsening headache, suggesting an early marker for PASC and the need for future multicenter studies to evaluate the impact of headache in PASC.

Authors/Disclosures
Teshamae Monteith, MD, FAAN (University of Miami) PRESENTER	Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for American Headache Society . Dr. Monteith has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for e-Neura. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Monteith has received personal compensation in the range of $0-$499 for serving as a Consultant for Merz. Dr. Monteith has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva . Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN . Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN . Dr. Monteith has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Cephalalgia. The institution of Dr. Monteith has received research support from AbbVie. The institution of Dr. Monteith has received research support from lilly. The institution of Dr. Monteith has received research support from Ipsen. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a ��ɫ�� with Medscape. Dr. Monteith has received personal compensation in the range of $500-$4,999 for serving as a ��ɫ�� with Massachusetts Medical Society . Dr. Monteith has a non-compensated relationship as a President Elect with Florida Society of Neurology that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a Editorial Board /Board Member with American Migraine Foundation that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a Board Member with International Headache Society that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Pfizer that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Abbvie that is relevant to AAN interests or activities. Dr. Monteith has a non-compensated relationship as a author with Theranica that is relevant to AAN interests or activities.
Alexandra N. Cocores, MD	Dr. Cocores has nothing to disclose.
Mejgan Mukhtarzada, MD (Geisinger Medical Center)	Dr. Mukhtarzada has nothing to disclose.
Natalia Rincon, MD (Columbia University)	Dr. Rincon has nothing to disclose.
Yensea M. Costas Encarnacion, MD	Dr. Costas Encarnacion has nothing to disclose.
	No disclosure on file
Evie Sobczak, MD (Mass General Hospital)	Ms. Sobczak has nothing to disclose.
Emily Swafford (University of Miami Miller School of Medicine)	Ms. Swafford has nothing to disclose.
	No disclosure on file
Tatjana Rundek, MD, PhD	The institution of Dr. Rundek has received research support from NIH.
Ayham Alkachroum	The institution of Ayham Alkachroum has received research support from NIH.

��ɫ����

��ɫ����

��ɫ��

��ɫ��